ERS Genomics

ERS is the world leader in licensing CRISPR/Cas9 technology for a wide variety of applications.
Our founder, Dr. Emmanuelle Charpentier (the ‘E’in ERS) won the Nobel Prize the discovery of CRISPR/Cas9 in 2020. 

Without question, CRISPR/Cas9 has transformed the field of gene editing. 
At ERS Genomics, our purpose is to extend global access to this technology and expand the boundaries of CRISPR potential.


BIO-Europe is the perfect time to start a conversation about your CRISPR license. We are excited to connect with companies who can benefit from this game-changing technology.
A meeting or a call with us is worthwhile for you if:

You are interested in possible use of CRISPR/Cas9 for internal research programs:
– Are you using modified cells or animals from an academic source?
– Are you generating in-house reagents?


You are interested in use of genetically modified cells in manufacturing. Including… 
– mAbs
– Gene or cell therapy
– Vectors
– Industrial enyzmes or intermediates


You provide any services which utilize CRISPR/Cas9 or cells or animals modified by the technology. Including…
– High-throughput screening 
– Target identification, Target validation
– Cell line development
– Disease specific cell models
– Animal models of disease


You have an interest in animal health applications. Including… 
Disease resistance, Vaccines Trait improvements

Let’s schedule a meeting in Basel

Schedule time with Dr. Ralph Vogelsang, Senior Director, Business Development & Licensing, ERS Genomics

‘Your journey with CRISPR begins with a license from ERS Genomics. I am delighted to be back at BIO 2023. If you would like to learn more about CRISPR/Cas9 and licensing, connect with me and let’s talk.’


Intellectual Property

Knowledge Centre

Contact US

Read More Of Our Articles

Explore more news on CRISPR/Cas9 and how it can provide a leading edge in the highly competitive biotech sector.

ERS Genomics and IRBM sign CRISPR/Cas9 license agreement

License agreement provides IRBM access to CRISPR gene editing technology to be applied across its drug discovery services offering Dublin, Ireland, and Rome, Italy, 20 May 2024: ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, and IRBM, a leader in the field of drug discovery, today announced a non-exclusive CRISPR/Cas9.

Read Full Article

ERS Genomics appoints John E Milad as Chief Executive Officer

Dublin, Ireland, 13 May 2024: ERS Genomics Limited (‘ERS’), the CRISPR licensing company, today announced the appointment of John E Milad as CEO, with immediate effect. John brings over 25 years of experience as an executive leader, venture capitalist, and investment banker focused on the life sciences and medical technology.

Read Full Article

Update: Key Charpentier/Doudna CRISPR patent upheld by China National Intellectual Property Administration

Patent Upheld by China National Intellectual Property Administration Dublin, Ireland, 26 March 2024: ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, today announced its patent CN201380038920.6 was upheld by the China National Intellectual Property Administration (CNIPA) in.

Read Full Article